tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

VIRX Stock Latest News

Xoma receives $8.1M milestone related to Day One’s sale of PRV
The FlyXoma receives $8.1M milestone related to Day One’s sale of PRV
1M ago
DAWN
VIRX
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
PremiumThe Fly
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
2M ago
DAWN
VIRX
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
PremiumThe Fly
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
2M ago
VIRX
Viracta Therapeutics Announces New Employment Inducement Grants
PremiumPress Releases
Viracta Therapeutics Announces New Employment Inducement Grants
2M ago
VIRX
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
PremiumCompany Announcements
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
2M ago
8K
VIRX
Viracta Therapeutics appoints Faerm as Chief Financial Officer
PremiumThe FlyViracta Therapeutics appoints Faerm as Chief Financial Officer
2M ago
VIRX
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
PremiumThe Fly
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
3M ago
VIRX
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
PremiumPress Releases
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
4M ago
VIRX
Viracta Therapeutics CFO Resigns, Interim Successor Appointed
PremiumCompany Announcements
Viracta Therapeutics CFO Resigns, Interim Successor Appointed
4M ago
8K
VIRX
Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
PremiumThe Fly
Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
5M ago
VIRX
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PremiumPress Releases
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
5M ago
VIRX
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
PremiumThe Fly
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
5M ago
VIRX
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe FlyOppenheimer biotech/healthcare analysts hold analyst/industry conference call
5M ago
VIRX
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
5M ago
VIRX
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
PremiumThe Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
5M ago
VIRX
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PremiumPress Releases
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
6M ago
VIRX
Viracta Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
PremiumThe Fly
Viracta Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
7M ago
VIRX
Viracta Therapeutics provides anticipated 2024 milestones
PremiumThe Fly
Viracta Therapeutics provides anticipated 2024 milestones
7M ago
VIRX
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
PremiumPress Releases
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
7M ago
VIRX
Viracta Therapeutics announces ODD granted by U.S. FDA to nana-val
PremiumThe FlyViracta Therapeutics announces ODD granted by U.S. FDA to nana-val
7M ago
VIRX
Viracta Therapeutics granted orphan status for carcinoma treatment
PremiumThe Fly
Viracta Therapeutics granted orphan status for carcinoma treatment
7M ago
VIRX
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
PremiumPress Releases
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
8M ago
VIRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >